@bimbo_1201: #fyp #bimbo_1201 #parati #Viral #tiktok #contenido

Valentina 🤍

Open In TikTok:

Region: US

Friday 23 August 2024 17:24:23 GMT

229113

16284

196

6521

Music

Download

No Watermark .mp4 (1.73MB) No Watermark(HD) .mp4 (1.73MB) Watermark .mp4 (1.98MB) Music .mp3

Comments

Elicet Durand ✨ :

Porque me estarán saliendo estos videos 🙄 será una señal?

2024-08-28 00:26:05

17

Mariam Corniel :

42 aplica?

2024-08-26 21:10:59

19

Mundo sobre ruedas 💛💙❤️ :

tengo 27. que hago entonces?

2024-09-12 16:57:30

0

Call me DanDan :

Jajaj🤣 que falte todo menos B12 🤝😏😎

2024-08-23 17:50:07

11

felipao21 :

si tengo 25 que necesito ?

2024-08-27 20:44:39

3

mnt :

Se me puso personal tiktok

2024-08-28 01:00:01

7

Ed de León :

34 ;)

2024-08-26 14:57:24

9

Evee👑 :

Pero se oficializa o no😩

2024-08-30 02:56:45

3

Yonathan Garcia Arauz :

Tú crees ?

2024-11-15 19:01:31

0

Kevin Jaime Romero J :

33

2024-08-27 19:38:44

2

dulcearenas86 :

38

2024-08-28 02:45:03

2

Maité :

49

2024-08-27 22:59:27

2

Darwin Andrés Herrer :

Confirmo 😎

2024-09-04 14:43:40

1

jluispc92 :

32😳

2024-08-27 04:07:13

1

albertopalomo180 :

siii ? no se lo.voy a pensar jajaja Jajaja

2024-08-24 02:04:29

2

barbaradrake.27 :

obvio

2024-08-26 00:16:18

1

pattycastillo :

lo tenia pero debía enseñarle cómo tratarme y no así no 😅😅

2024-08-28 20:28:27

1

Victor Vargas :

34

2024-09-04 16:53:37

1

Edward Martinez :

epa la arepas, 😏😏😏😏

2024-09-04 17:18:18

1

mauriciomenacho69 :

33

2024-08-27 03:49:36

1

edder Harim 🎩 :

consentir bbs es mi hobbie 😎

2024-08-24 17:00:21

2

ARES 🥷🏻✨ :

Sabeeee 😎

2024-08-26 21:41:40

1

Freddbadboy87 :

True story 👏

2024-08-27 18:28:07

1

El Fercho :

33🤫🤫

2024-08-26 18:40:58

1

Eric 😉 :

Tu si sabes 🤭

2024-08-26 14:36:02

1

To see more videos from user @bimbo_1201, please go to the Tikwm homepage.

Other Videos

📣 The NATALEE study looked at using ribociclib (Kisqali) x 3 years in combination with an aromatase inhibitor for stage 2-3 hormone receptor positive/HER2 negative breast cancer (including lymph node negative patients) to see if it can further reduce risk of recurrence. ⭐️ The data now presented at @ascocancer #ASCO24 by Yardley D et al. looks at the node negative population. 🔸 613 patients included in this analysis: -Tumor size >2cm, grade 3 or grade 2 AND Ki67>=20% or tumor size >2cm AND high genomic risk (Oncotype >=26, high Mammaprint etc) -Patients with tumor size >5cm -Patients with skin/chest wall involvement ❓What did they find in the node negative population? ⭐️ Ribociclib + AI reduced risk of invasive recurrence or death by 28% (93.2% alive without recurrence at 3 years in ribociclib + AI arm versus 90.6% in AI alone arm) 🚫24% of patients discontinued treatment in the ribociclib+AI arm versus 8% in the AI arm alone Take Home 🏡 Points and Remaining Questions? 🎉 Very reassuring to see the benefit of ribociclib in the node negative population (Verzenio is only approved for node positive) 💃 These results may allow us to treat a broader population than we do currently with CDK 4/6 inhibitors and endocrine therapy ❓Should everyone who is eligible get it? For example, does a patient with a 2cm grade 2 tumor with Oncotype 26 have same benefit as a 4.9cm tumor, grade 3, Oncotype 38? Is 2.5% benefit worth it for everyone? 💊 Need to balance benefit with toxicity (as we do for every drug) (this drug needs initial EKG 🫀monitoring). Other side effects: low blood 🩸counts, joint pain, and liver related events among others. ⏰ What will longer follow up data show? Will benefit change increase time as we know hormone receptor positive breast cancers can have late recurrences? 🚨Not yet FDA approved but recent ASCO guideline does support its use (check out my recent video if you missed it!) Questions?! Comments?! #breastcancer #ribociclib #kisqali #oncologist

📣 The NATALEE study looked at using ribociclib (Kisqali) x 3 years in combination with an aromatase inhibitor for stage 2-3 hormone receptor positive/HER2 negative breast cancer (including lymph node negative patients) to see if it can further reduce risk of recurrence. ⭐️ The data now presented at @ascocancer #ASCO24 by Yardley D et al. looks at the node negative population. 🔸 613 patients included in this analysis: -Tumor size >2cm, grade 3 or grade 2 AND Ki67>=20% or tumor size >2cm AND high genomic risk (Oncotype >=26, high Mammaprint etc) -Patients with tumor size >5cm -Patients with skin/chest wall involvement ❓What did they find in the node negative population? ⭐️ Ribociclib + AI reduced risk of invasive recurrence or death by 28% (93.2% alive without recurrence at 3 years in ribociclib + AI arm versus 90.6% in AI alone arm) 🚫24% of patients discontinued treatment in the ribociclib+AI arm versus 8% in the AI arm alone Take Home 🏡 Points and Remaining Questions? 🎉 Very reassuring to see the benefit of ribociclib in the node negative population (Verzenio is only approved for node positive) 💃 These results may allow us to treat a broader population than we do currently with CDK 4/6 inhibitors and endocrine therapy ❓Should everyone who is eligible get it? For example, does a patient with a 2cm grade 2 tumor with Oncotype 26 have same benefit as a 4.9cm tumor, grade 3, Oncotype 38? Is 2.5% benefit worth it for everyone? 💊 Need to balance benefit with toxicity (as we do for every drug) (this drug needs initial EKG 🫀monitoring). Other side effects: low blood 🩸counts, joint pain, and liver related events among others. ⏰ What will longer follow up data show? Will benefit change increase time as we know hormone receptor positive breast cancers can have late recurrences? 🚨Not yet FDA approved but recent ASCO guideline does support its use (check out my recent video if you missed it!) Questions?! Comments?! #breastcancer #ribociclib #kisqali #oncologist

#الشعب_الصيني_ماله_حل😂😂 #الريتش_في_زمه_الله💔😣 #money #فلوس_التيك_توك #فلوس_ابويا

#الشعب_الصيني_ماله_حل😂😂 #الريتش_في_زمه_الله💔😣 #money #فلوس_التيك_توك #فلوس_ابويا

📣 The NATALEE study looked at using ribociclib (Kisqali) x 3 years in combination with an aromatase inhibitor for stage 2-3 hormone receptor positive/HER2 negative breast cancer (including lymph node negative patients) to see if it can further reduce risk of recurrence. ⭐️ The data now presented at @ascocancer #ASCO24 by Yardley D et al. looks at the node negative population. 🔸 613 patients included in this analysis: -Tumor size >2cm, grade 3 or grade 2 AND Ki67>=20% or tumor size >2cm AND high genomic risk (Oncotype >=26, high Mammaprint etc) -Patients with tumor size >5cm -Patients with skin/chest wall involvement ❓What did they find in the node negative population? ⭐️ Ribociclib + AI reduced risk of invasive recurrence or death by 28% (93.2% alive without recurrence at 3 years in ribociclib + AI arm versus 90.6% in AI alone arm) 🚫24% of patients discontinued treatment in the ribociclib+AI arm versus 8% in the AI arm alone Take Home 🏡 Points and Remaining Questions? 🎉 Very reassuring to see the benefit of ribociclib in the node negative population (Verzenio is only approved for node positive) 💃 These results may allow us to treat a broader population than we do currently with CDK 4/6 inhibitors and endocrine therapy ❓Should everyone who is eligible get it? For example, does a patient with a 2cm grade 2 tumor with Oncotype 26 have same benefit as a 4.9cm tumor, grade 3, Oncotype 38? Is 2.5% benefit worth it for everyone? 💊 Need to balance benefit with toxicity (as we do for every drug) (this drug needs initial EKG 🫀monitoring). Other side effects: low blood 🩸counts, joint pain, and liver related events among others. ⏰ What will longer follow up data show? Will benefit change increase time as we know hormone receptor positive breast cancers can have late recurrences? 🚨Not yet FDA approved but recent ASCO guideline does support its use (check out my recent video if you missed it!) Questions?! Comments?! #breastcancer #ribociclib #kisqali #oncologist

📣 The NATALEE study looked at using ribociclib (Kisqali) x 3 years in combination with an aromatase inhibitor for stage 2-3 hormone receptor positive/HER2 negative breast cancer (including lymph node negative patients) to see if it can further reduce risk of recurrence. ⭐️ The data now presented at @ascocancer #ASCO24 by Yardley D et al. looks at the node negative population. 🔸 613 patients included in this analysis: -Tumor size >2cm, grade 3 or grade 2 AND Ki67>=20% or tumor size >2cm AND high genomic risk (Oncotype >=26, high Mammaprint etc) -Patients with tumor size >5cm -Patients with skin/chest wall involvement ❓What did they find in the node negative population? ⭐️ Ribociclib + AI reduced risk of invasive recurrence or death by 28% (93.2% alive without recurrence at 3 years in ribociclib + AI arm versus 90.6% in AI alone arm) 🚫24% of patients discontinued treatment in the ribociclib+AI arm versus 8% in the AI arm alone Take Home 🏡 Points and Remaining Questions? 🎉 Very reassuring to see the benefit of ribociclib in the node negative population (Verzenio is only approved for node positive) 💃 These results may allow us to treat a broader population than we do currently with CDK 4/6 inhibitors and endocrine therapy ❓Should everyone who is eligible get it? For example, does a patient with a 2cm grade 2 tumor with Oncotype 26 have same benefit as a 4.9cm tumor, grade 3, Oncotype 38? Is 2.5% benefit worth it for everyone? 💊 Need to balance benefit with toxicity (as we do for every drug) (this drug needs initial EKG 🫀monitoring). Other side effects: low blood 🩸counts, joint pain, and liver related events among others. ⏰ What will longer follow up data show? Will benefit change increase time as we know hormone receptor positive breast cancers can have late recurrences? 🚨Not yet FDA approved but recent ASCO guideline does support its use (check out my recent video if you missed it!) Questions?! Comments?! #breastcancer #ribociclib #kisqali #oncologist

like jennie bekasi version, ib @meo mãi mận

like jennie bekasi version, ib @meo mãi mận

📣 The NATALEE study looked at using ribociclib (Kisqali) x 3 years in combination with an aromatase inhibitor for stage 2-3 hormone receptor positive/HER2 negative breast cancer (including lymph node negative patients) to see if it can further reduce risk of recurrence. ⭐️ The data now presented at @ascocancer #ASCO24 by Yardley D et al. looks at the node negative population. 🔸 613 patients included in this analysis: -Tumor size >2cm, grade 3 or grade 2 AND Ki67>=20% or tumor size >2cm AND high genomic risk (Oncotype >=26, high Mammaprint etc) -Patients with tumor size >5cm -Patients with skin/chest wall involvement ❓What did they find in the node negative population? ⭐️ Ribociclib + AI reduced risk of invasive recurrence or death by 28% (93.2% alive without recurrence at 3 years in ribociclib + AI arm versus 90.6% in AI alone arm) 🚫24% of patients discontinued treatment in the ribociclib+AI arm versus 8% in the AI arm alone Take Home 🏡 Points and Remaining Questions? 🎉 Very reassuring to see the benefit of ribociclib in the node negative population (Verzenio is only approved for node positive) 💃 These results may allow us to treat a broader population than we do currently with CDK 4/6 inhibitors and endocrine therapy ❓Should everyone who is eligible get it? For example, does a patient with a 2cm grade 2 tumor with Oncotype 26 have same benefit as a 4.9cm tumor, grade 3, Oncotype 38? Is 2.5% benefit worth it for everyone? 💊 Need to balance benefit with toxicity (as we do for every drug) (this drug needs initial EKG 🫀monitoring). Other side effects: low blood 🩸counts, joint pain, and liver related events among others. ⏰ What will longer follow up data show? Will benefit change increase time as we know hormone receptor positive breast cancers can have late recurrences? 🚨Not yet FDA approved but recent ASCO guideline does support its use (check out my recent video if you missed it!) Questions?! Comments?! #breastcancer #ribociclib #kisqali #oncologist

📣 The NATALEE study looked at using ribociclib (Kisqali) x 3 years in combination with an aromatase inhibitor for stage 2-3 hormone receptor positive/HER2 negative breast cancer (including lymph node negative patients) to see if it can further reduce risk of recurrence. ⭐️ The data now presented at @ascocancer #ASCO24 by Yardley D et al. looks at the node negative population. 🔸 613 patients included in this analysis: -Tumor size >2cm, grade 3 or grade 2 AND Ki67>=20% or tumor size >2cm AND high genomic risk (Oncotype >=26, high Mammaprint etc) -Patients with tumor size >5cm -Patients with skin/chest wall involvement ❓What did they find in the node negative population? ⭐️ Ribociclib + AI reduced risk of invasive recurrence or death by 28% (93.2% alive without recurrence at 3 years in ribociclib + AI arm versus 90.6% in AI alone arm) 🚫24% of patients discontinued treatment in the ribociclib+AI arm versus 8% in the AI arm alone Take Home 🏡 Points and Remaining Questions? 🎉 Very reassuring to see the benefit of ribociclib in the node negative population (Verzenio is only approved for node positive) 💃 These results may allow us to treat a broader population than we do currently with CDK 4/6 inhibitors and endocrine therapy ❓Should everyone who is eligible get it? For example, does a patient with a 2cm grade 2 tumor with Oncotype 26 have same benefit as a 4.9cm tumor, grade 3, Oncotype 38? Is 2.5% benefit worth it for everyone? 💊 Need to balance benefit with toxicity (as we do for every drug) (this drug needs initial EKG 🫀monitoring). Other side effects: low blood 🩸counts, joint pain, and liver related events among others. ⏰ What will longer follow up data show? Will benefit change increase time as we know hormone receptor positive breast cancers can have late recurrences? 🚨Not yet FDA approved but recent ASCO guideline does support its use (check out my recent video if you missed it!) Questions?! Comments?! #breastcancer #ribociclib #kisqali #oncologist

Satisfying Strawberry Cheesecake Wax slime asmr 🍓 #satisfyingvideo #asmr #wax #asmrsounds #crunch #cracking #asmrsound #slime #foryou #sponge #foryoupage #asmrvideo #bubbles #asmrtiktoks #crackling #satisfying

Satisfying Strawberry Cheesecake Wax slime asmr 🍓 #satisfyingvideo #asmr #wax #asmrsounds #crunch #cracking #asmrsound #slime #foryou #sponge #foryoupage #asmrvideo #bubbles #asmrtiktoks #crackling #satisfying

About

Robot

Legal

Privacy Policy